Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Chidamide for HIV Functional Cure
NCT06902038Not yet recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Randomised, single-blind trial of sintilimab and tucidinostat in human immunodeficiency virus type 1 infection (HIV-1) (3 arms). Primary endpoint: Time interval from antiretroviral therapy interruption to antiretroviral treatment restart at 12 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
sintilimabtucidinostat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06902038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902038.